Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice

Journal of Nuclear Medicine

Volumn 51, Issue 8, 2010, Pages 1285-1292

  Walter, Martin A ^a   Hildebrandt, Isabel J ^a   Hacke, Katrin ^a   Kesner, Adam L ^a   Kelly, Owen ^a   Lawson, Gregory W ^a   Phelps, Michael E ^a   Czernin, Johannes ^a   Weber, Wolfgang A ^a,b   Schiestl, Robert H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Knock out mice; Metabolic imaging; Molecular imaging; p53; Treatment monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GEMCITABINE; GLUCOSE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; PROTEIN P53; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER CHEMOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; GLUCOSE METABOLISM; GOLD STANDARD; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMUS LYMPHOMA; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR GROWTH; AGING; ANIMAL; CELL PROLIFERATION; DISEASE COURSE; GENETICS; IMAGE PROCESSING; LYMPHOMA; MITOSIS INDEX; MOUSE MUTANT; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; THYMOMA;

AGING; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DEOXYCYTIDINE; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPHOMA; MICE; MICE, KNOCKOUT; MITOTIC INDEX; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYMUS NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956210819     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.073585     Document Type: Article

References (42)

1. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer. 2007;7:645-658.
2. Carver BS, Pandolfi PP. Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res. 2006;12:5305-5311.
3. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol. 1998;16:3158-3168.
4. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood. 1994;84:2412-2421.
5. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408:307-310.
6. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994-2004.
7. Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 1993;82:2289-2295.
8. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood. 1995;86:4587-4593.
9. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351-3359.
10. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101:1220-1235.
11. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in Hodgkin's or non-Hodgkin's lymphoma. Ann Hematol. 2001;80:2-8. (Pubitemid 32156757)
12. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-221.
13. Tsukada T, Tomooka Y, Takai S, et al. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene. 1993;8:3313-3322.
14. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53- mutant mice. Curr Biol. 1994;4:1-7.
15. Purdie CA, Harrison DJ, Peter A, et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene. 1994;9: 603-609.
16. Attardi LD, Donehower LA. Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 2005;576:4-21.
17. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 1994;79:329-339. (Pubitemid 24324922)
18. Difilippantonio MJ, Zhu J, Chen HT, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature. 2000;404: 510-514.
19. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med. 2005;11:1306-1313.
20. Wloga EH, Criniti V, Yamasaki L, Bronson RT. Lymphomagenesis and female-specific lethality in p53-deficient mice occur independently of E2f1. Nat Cell Biol. 2004;6:565-567, author reply 567-568. (Pubitemid 38960907)
21. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507-3516.
22. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
23. Samper E, Morgado L, Estrada JC, et al. Increase in mitochondrial biogenesis, oxidative stress, and glycolysis in murine lymphomas. Free Radic Biol Med. 2009;46:387-396.
24. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10:611-618.
25. Abbey CK, Borowsky AD, McGoldrick ET, et al. In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci USA. 2004;101:11438-11443.
26. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health; 1985. NIH publication 85-23.
27. Suckow C, Kuntner C, Chow P, Silverman R, Chatziioannou A, Stout D. Multimodality rodent imaging chambers for use under barrier conditions with gas anesthesia. Mol Imaging Biol. 2009;11:100-106.
28. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
29. Hsu HC, Zhang HG, Li L, et al. Age-related thymic involution in C57BL/6J x DBA/2J recombinant-inbred mice maps to mouse chromosomes 9 and 10. Genes Immun. 2003;4:402-410.
30. Bensaad K, Vousden KH. p53: new roles in metabolism. Trends Cell Biol. 2007;17:286-291.
31. Kawauchi K, Araki K, Tobiume K, Tanaka N. Loss of p53 enhances catalytic activity of IKKβ through O-linked β-N-acetyl glucosamine modification. Proc Natl Acad Sci USA. 2009;106:3431-3436.
32. Flores JE, McFarland LM, Vanderbilt A, Ogasawara AK, Williams SP. The effects of anesthetic agent and carrier gas on blood glucose and tissue uptake in mice undergoing dynamic FDG-PET imaging: sevoflurane and isoflurane compared in air and in oxygen. Mol Imaging Biol. 2008;10:192-200.
33. 18F-FDG imaging of lung metastasis tumors using small animal PET. Nucl Med Biol. 2008;35: 143-150.
34. Oki Y, Younes A. Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leuk Lymphoma. 2008;49:883-889. (Pubitemid 351942740)
35. Chau I, Watkins D, Cunningham D. Gemcitabine and its combinations in the treatment of malignant lymphoma. Clin Lymphoma. 2002;3:97-104.
36. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer. 2001;1:68-76.
37. Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX- 015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 2000;60:1193-1196.
38. Horowitz J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther. 1999;1: 500-509.
39. Shimada H, Matsubara H, Shiratori T, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 2006;97:554-561.
40. Wolf JK, Bodurka DC, Gano JB, et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol. 2004;94:442-448.
41. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 2003;4:415-422.
42. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998;17:279-284. (Pubitemid 29210167)